Detalles de la búsqueda
1.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet
; 403(10441): 2293-2306, 2024 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705160
2.
Decision-Making among Experts in Advanced Hodgkin Lymphoma.
Oncology
; 101(3): 159-165, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103806
3.
Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.
Hematol Oncol
; 40(4): 716-723, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35574642
4.
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Blood
; 134(4): 353-362, 2019 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101627
5.
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
BMC Cancer
; 20(1): 166, 2020 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32111181
6.
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
Lancet Oncol
; 18(4): 454-463, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28236583
7.
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
Br J Haematol
; 176(5): 770-782, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27983764
8.
Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Hematol Oncol
; 35(4): 890-893, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27641727
9.
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.
Support Care Cancer
; 25(9): 2833-2842, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28405846
10.
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Br J Haematol
; 174(2): 255-63, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27018242
11.
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Blood
; 133(5): 494-497, 2019 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-30455380
12.
Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.
Cancer Invest
; 34(8): 361-72, 2016 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27635469
13.
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Haematologica
; 101(3): 346-55, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26659919
14.
Improved survival of older patients with multiple myeloma in the era of novel agents.
Hematol Oncol
; 34(4): 217-223, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25898820
15.
Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience.
Support Care Cancer
; 24(5): 2119-2128, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26553033
16.
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Blood
; 132(19): 2097-2100, 2018 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30237154
17.
Outcome of mantle cell lymphoma patients treated at a single institution over the past decade.
Hematol Oncol
; 32(4): 192-6, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24338732
18.
Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.
Hematol Oncol
; 36(1): 370-371, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28681549
19.
The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients.
BMC Med Inform Decis Mak
; 13: 93, 2013 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-23971904
20.
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
EClinicalMedicine
; 64: 102221, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37781158